The company plans to launch a larger mid-stage study in the second half of 2024 and a late-stage trial in 2026
Efficacy is on par with injectable semaglutide with up to 1.7% reduction on the highest dose, and change in fasting glucose from -30 to -42mg/dl which is a significant improvement in glycemia
[DOI] [PubMed] [Google Scholar] 25.Seiwerth S., Milavic M., Vukojevic J., Gojkovic S., Krezic I., Vuletic L.B., Horvat Pavlov K., Petrovic A., Sikiric S., Vranes H., et al
To accelerate progress in manufactured islet cell therapies, the panelists agreed that the top priorities are: More companies exploring novel approaches Expanding eligibility criteria for trialsand incoporating the perspectives of the T1D community into regulatory decisionsso we can build more evidence around the safety and efficacy of manufactured islet cell therapies Additional frameworks to help guide the field, like our cell therapies roadmap and upcoming publications from Breakthrough T1D staff around manufacturing and preclinical considerations Optimizing manufacturing processes to reduce costs and ensure access for people who want these therapies Optimizing cell therapy products by reducing or eliminating the need for immunosuppression and finding the best transplant site for survival Brynn Marks, M.D., Senior Director of Medical Affairs, chaired a session about the promise and perspective of islet cell replacement therapies for kids with T1D
